ML213

Item no.	HY-101843-5mg
Manufacturer	MedChem Express
CASRN	489402-47-3
Amount	5 mg
Category	Oncology Cardiovascular Research Ischemia & Reperfusion Injury Hypertension Inhibitors & Compound Libraries Small Molecules Arrhythmias By Organ Skin Cancer
Type	Inhibitors
Purity	99.79
Formula	C17H23NO
Citations	[1]Brueggemann LI, et al. Differential activation of vascular smooth muscle Kv7.4, Kv7.5, and Kv7.4/7.5 channels by ML213 and ICA-069673. Mol Pharmacol. 2014 Sep;86(3):330-41. [2]Jepps TA, et al. Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370. Br J Pharmacol. 2014 Oct;171(19):4413-24. [3]Yu H, et al. Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. ACS Chem Neurosci. 2011 Oct 19;2(10):572-577.
Smiles	O=C(C1C(C2)CCC2C1)NC3=C(C)C=C(C)C=C3C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	489402-47-3
Available
Product Description	ML213 is a selective activator of Kv7.2 and Kv7.4 channels, enhances Kv7.2 and Kv7.4 channels with EC50s of 230 and 510 nM, respectively.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Neuroscience-Neuromodulation
Molecular Weight	257.37
Clinical Information	No Development Reported
Solubility	DMSO : 36.67 mg/mL (ultrasonic)
Pathway	Membrane Transporter/Ion Channel
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-101843-5mg-safety-datasheet.pdf